SS Innovations International (NasdaqCM:SSII) opened 2026 with Q1 revenue of about US$11.1 million and a basic EPS loss of US$0.02, while trailing 12 month figures show revenue of roughly US$48.5 million and a basic EPS loss of US$0.05. Over the past reported quarters, revenue has ranged from about US$5.1 million in Q1 2025 to US$14.5 million in Q4 2025, with basic EPS losses moving between roughly US$0.00 and US$0.03 per share. Investors are therefore likely to focus on how efficiently that top line is translating into margins and whether recent revenue levels are doing enough to contain ongoing losses.

See our full analysis for SS Innovations International.

With the headline numbers in place, the next step is to line these results up against the most common narratives around SS Innovations International to see which views the data backs up and which ones start to look less convincing.

Losses Persist Around US$10 Million Over TTM

• On a trailing 12 month basis, SS Innovations International reported revenue of about US$48.5 million and a net loss of roughly US$10.0 million, compared with a Q1 2026 loss of US$3.6 million on US$11.1 million of revenue.
• Bears often point to the five year annualized loss expansion of 18.2% as a sign that profitability is under pressure. The latest TTM net loss of about US$10.0 million alongside a basic EPS loss of US$0.05 gives clear support to that bearish concern.
  • Critics highlight that Q1 2026 alone saw a net loss of about US$3.6 million, which sits within a run of quarterly losses ranging from roughly US$0.3 million to US$5.7 million over the past six reported quarters.
  • What stands out for bearish investors is that even as TTM revenue sits near US$48.5 million, trailing results still show no positive net margin. This aligns with the view that the business is not yet absorbing its cost base.

P/S Of 16.5x Versus 2.7x Industry

• The stock trades on a P/S of 16.5x, which sits above both the peer average of 7.7x and the wider US Medical Equipment industry average of 2.7x, while the current share price is US$3.99.
• Bears argue that paying a 16.5x P/S multiple for a company with trailing 12 month net losses of about US$10.0 million is a valuation risk, and the data here strongly supports that bearish angle.
  • With trailing revenue of roughly US$48.5 million and no positive earnings, the high P/S multiple rests entirely on sales, while five year losses have expanded at about 18.2% a year.
  • Given that analysts could not produce earnings or revenue forecasts from the available inputs, skeptics see the premium multiple as disconnected from any quantified improvement in profitability.

On these numbers, skeptics see a stock priced far richer than the industry while still carrying widening losses, and that tension sits at the heart of many cautious takes on SS Innovations International. 🐻 SS Innovations International Bear Case

Revenue Scales, But Profit Stays Negative

• Quarterly revenue moved between about US$5.1 million and US$14.5 million across the last six reported quarters, yet each of those periods still recorded a net loss, including Q1 2026 revenue of roughly US$11.1 million against a loss of about US$3.6 million.
• Supporters of the broader growth story often focus on the commercial stage product ecosystem across surgical robots and digital tools, and these figures partly back the idea that the company is generating real sales, but they also show that profitability has not followed that narrative yet.
  • Across the last six reported quarters, net losses ranged from about US$0.3 million to US$5.7 million, and basic EPS stayed in loss territory between roughly US$0.00 and US$0.03 per share.
  • At the same time, trailing 12 month revenue was about US$48.5 million versus US$20.6 million in the earliest period provided, which shows a larger revenue base paired with a TTM basic EPS loss of about US$0.05.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on SS Innovations International's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Concerned by the tone of these results, or wondering if the market reaction matches the actual risk profile? Now is the time to look closely at the underlying data and stress test your own thesis before sentiment moves on. To round out your view, take a moment to review the 1 important warning sign.

See What Else Is Out There

SS Innovations International is still reporting consistent losses and trades on a much higher P/S multiple than the industry, without supporting profitability.

If you are uneasy about paying a premium for ongoing losses, it makes sense to compare opportunities with stronger value signals using the 48 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.